Compare OTH & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTH | LUNG |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.2M | 72.2M |
| IPO Year | N/A | 2020 |
| Metric | OTH | LUNG |
|---|---|---|
| Price | $2.59 | $1.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 33.3K | ★ 376.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,789,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | $600.18 | ★ N/A |
| Revenue Growth | N/A | ★ 22.01 |
| 52 Week Low | $1.95 | $1.31 |
| 52 Week High | $3.75 | $8.71 |
| Indicator | OTH | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 43.56 |
| Support Level | $2.03 | $1.51 |
| Resistance Level | $2.72 | $1.93 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 74.20 | 49.18 |
Off The Hook YS Inc operates as a nationwide leader in the yacht and boat dealership industry, offering a comprehensive suite of services that spans the entire boat value chain. The company operates as two segments: Boat Sales and Azure Funding. Boat Sales includes Specializing in the buying, selling, and wholesaling of yachts and boats, having a boat dealership created to run Yellow Fin sales in Miami; and Azure Funding includes a recreational loan broker and lender providing financing solutions for individuals, dealerships, and brokerages.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.